Patiromer

Drug Profile

Patiromer

Alternative Names: ILY-105; Patiromer calcium; Patiromer for Oral Suspension; Patiromer FOS; Patiromer sorbitex calcium; RLY-105; RLY-5016; RLY-5016S; RLY5016 for Oral Suspension; Veltassa

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Relypsa
  • Developer Relypsa; Vifor Fresenius Medical Care Renal Pharma
  • Class Polymers
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperkalaemia

Most Recent Events

  • 19 May 2017 Preregistration for Hyperkalaemia in Switzerland, Australia (PO) prior to May 2017
  • 19 May 2017 The Committee for Medicinal Products for Human Use recommends approval of patiromer for Hyperkalaemia in European Union/European Economic Area
  • 21 Apr 2017 Relypsa plans a phase II trial for Hyperkalemia (in Child, In Adolescents) in USA, Bulgaria, Georgia, Germany, Poland, South Africa and Ukraine (NCT03087058)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top